The T102C Polymorphism of the 5-HT2A-Receptor Gene in Fibromyalgia

Brigitta Bondy; Michael Spaeth; Martin Offenbaecher; Karin Glatzeder; Thomas Stratz; Markus Schwarz; Sylvia de Jonge; Marc Krüger; Rolf R. Engel; Lothar Färber; Dieter E. Pongratz; Manfred Ackenheil

Neurobiology of Disease (Oct 1999)

The T102C Polymorphism of the 5-HT2A-Receptor Gene in Fibromyalgia

Brigitta Bondy,
Michael Spaeth,
Martin Offenbaecher,
Karin Glatzeder,
Thomas Stratz,
Markus Schwarz,
Sylvia de Jonge,
Marc Krüger,
Rolf R. Engel,
Lothar Färber,
Dieter E. Pongratz,
Manfred Ackenheil

Affiliations

Brigitta Bondy: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Michael Spaeth: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Martin Offenbaecher: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Karin Glatzeder: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Thomas Stratz: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Markus Schwarz: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Sylvia de Jonge: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Marc Krüger: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Rolf R. Engel: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Lothar Färber: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Dieter E. Pongratz: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany
Manfred Ackenheil: Psychiatric Hospital, University of Munich, Nußbaumstraße 7, D-80336, Munich, Germany; Friedrich-Baur-Institute, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Department of Physical Medicine and Rehabilitation, University of Munich, Ziemssenstraße 1a, D-80336, Munich, Germany; Clinic of Rheumatology, Hochrhein Institute, Bergseestraße 61, D-79713, Bad Säckingen, Germany; Novartis Pharma GmbH, Deutschherrenstraße 15, D-90429, Nürnberg, Germany

Journal volume & issue: Vol. 6, no. 5
pp. 433 – 439

Abstract

Read online

Based on a possible involvement of serotonergic dysfunction in the pathophysiology of fibromyalgia (FM) and on preliminary reports of a possible genetically driven vulnerability for this disorder we investigated the silent T102C polymorphism of the 5-HT2A-receptor gene in 168 FM patients and 115 healthy controls. Our results showed a significantly different genotype distribution in FM patients with a decrease in T/T and an increase in both T/C and C/C genotypes as compared to the control population (Fisher's Exact test, two-sided, P=0.008). However, the increase in allele-C102 frequency felt short of significance (P=0.07). Correlation of genotypes to clinical parameters revealed no influences on age of onset, duration of disease or psychopathological symptoms, measured with the Beck Depression Inventory and the symptom checklist SCL-90-R. In contrast to that the pain score, being a self reported information on pain severity, was significantly higher in patients of the T/T genotype (Mann–Whitney U test, P=0.028). This suggests that the T102-allele might be involved in the complex circuits of nociception. However, the T102C polymorphism is not directly involved in the aetiology of FM but might be in linkage dysequilibrium with the true functional variant, which has to be unravelled.

Published in Neurobiology of Disease

ISSN: 0969-9961 (Print); 1095-953X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.journals.elsevier.com/neurobiology-of-disease

About the journal

Abstract

Keywords